Cite
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden.
MLA
Storandt, Michael H., et al. “Pembrolizumab near the End of Life in Patients with Metastatic Pancreatic Cancer: A Multi-Site Consecutive Series to Examine Survival and Patient Treatment Burden.” Cancer Immunology, Immunotherapy : CII, vol. 72, no. 7, July 2023, pp. 2515–20. EBSCOhost, https://doi.org/10.1007/s00262-023-03397-4.
APA
Storandt, M. H., Tran, N., Martin, N., & Jatoi, A. (2023). Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Cancer Immunology, Immunotherapy : CII, 72(7), 2515–2520. https://doi.org/10.1007/s00262-023-03397-4
Chicago
Storandt, Michael H, Nguyen Tran, Nichole Martin, and Aminah Jatoi. 2023. “Pembrolizumab near the End of Life in Patients with Metastatic Pancreatic Cancer: A Multi-Site Consecutive Series to Examine Survival and Patient Treatment Burden.” Cancer Immunology, Immunotherapy : CII 72 (7): 2515–20. doi:10.1007/s00262-023-03397-4.